Abstract
Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Eleven studies were included in the final assessment. Pooled three- and five-year OS rates were 58.60% and 42.19%, respectively. The estimated pooled three- and five-year DFS rates were 23.47% and 14.26%, respectively.
Highlights
BackgroundWorldwide, colorectal cancer (CRC) is the second most common cancer in women and the third most common in men
In the past few decades, such patients have instead been managed with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) [6,7,8,9,10,11,12,13]
We present here the summary estimate of the overall survival (OS) and disease-free survival (DFS) for the studies that reported them
Summary
Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men. The global incidence of CRC in 2018 accounted for 10.2% of all cancers [1]. Peritoneal carcinomatosis (PC) affects around 30% to 40% of patients with CRC, 5% to 10% of whom will have the synchronous disease [2,3]. It is the sole metastasis site in approximately 25% of patients [4]. Patients presenting with PC arising from CRC previously received palliative treatment, in carefully selected patients, it is no longer considered a terminal condition [5]. In the past few decades, such patients have instead been managed with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) [6,7,8,9,10,11,12,13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
